Table 2

The decrease in log10 HBV DNA in the three groups of patients at weeks 24 and 48 (per-protocol and intention-to-treat analyses)

Log10 serum HBV DNA (IU/mL)Besifovir 90 mg (PP n=33; ITT n=36)Besifovir 150 mg (PP n=35; ITT n=39)Entecavir 0.5 mg (PP n=36; ITT n=39)
Baseline
Mean (±SD)
 PP6.9 (±1.2)6.96 (±1.44)7.12 (±1.28)
 ITT6.8 (±1.27)6.79 (±1.7)6.98 (±1.45)
Week 24
Mean (±SD)
 PP1.92 (±0.77)1.85 (±0.78)1.84 (±0.81)
 ITT1.94 (±0.81)1.92 (±0.99)1.81 (±0.79)
Week 48
Mean (±SD)
 PP1.61 (±0.51)1.64 (±0.76)1.57 (±0.58)
 ITT1.67 (±0.57)1.72 (±1)1.56 (±0.56)
Decrease at week 24 from baseline
Mean (±SD)
 PP−4.98 (±0.84)−5.11 (±1.07)−5.28 (±1.04)
 Two-sided 90% CI of difference*−0.301 (−0.682 to 0.081)−0.17 (−0.587 to 0.247)NA
 ITT−4.86 (±0.97)−4.87 (±1.37)−5.16 (±1.2)
 Two-sided 90% CI of difference*−0.306 (−0.727 to 0.115)−0.294 (−0.779 to 0.191)NA
Decrease at week 48 from baseline
Mean (±SD)
 PP−5.30 (±0.99)−5.32 (±1.26)−5.55 (±1.17)
 Two-sided 90% CI of difference*−0.254 (−0.69 to 0.182)−0.227 (−0.708 to 0.254)NA
 ITT−5.13 (±1.26)−5.07 (±1.54)−5.41 (±1.33)
 Two-sided 90% CI of difference*−0.285 (−0.783 to 0.213)−0.346 (−0.889 to 0.196)NA
  • *The difference of the log10 HBV DNA decrease of the entecavir group and the besifovir group.

  • HBV, hepatitis B virus; ITT, intention-to-treat; PP, Per protocol.